News | November 08, 2013

Zevacor Molecular Awards IBA Contract to Build Only U.S. Commercial Cyclotron for Sr-82 Production

Cyclone 70 to stabilize U.S. supply of strontium 82/rubidium 82 generators for use in diagnosis of cardiovascular disease

cyclone 70 zevacor IBM nuclear imaging radiopharmaceuticals and tracers PET
November 8, 2013 — Zevacor Molecular, a healthcare firm that manufactures and distributes positron emissions tomography (PET) and single photon emission computed tomography (SPECT) radiopharmaceuticals, has purchased the first 70 MeV Cyclotron dedicated to medical use in the United States from Ion Beam Applications, S.A. (IBA).
 
The purchase of IBA’s Cyclone 70 is the first of several investments Zevacor is making to secure the future of nuclear medicine and molecular imaging. The 70 MeV Cyclotron is expected to be operational in the fall of 2016 and will help to stabilize the domestic supply of medical isotopes needed to diagnose and treat critical illnesses. 
 
Strontium 82 (Sr-82) has a half-life of about 25 days, allowing it to be easily shipped to imaging facilities for about a month of use. It is shipped as a generator unit to produce rubidium 82 (Rb-82) at the point of imaging, since Rb-82 has a half-life of only 75 seconds. The isotope is primarily used for nuclear myocardial perfusion exams.
 
In addition to the cyclotron, Zevacor will also invest in significant infrastructure to create a state-of-the-art manufacturing facility to house the Cyclone 70 as well as other cyclotrons and manufacturing equipment. It expects to determine the location by the end of 2013.
 
“This is just the beginning,” said John Zehner, executive vice president and chief operating officer, Zevacor Molecular. “With strategic investments like the purchase of the Cyclone 70, Zevacor and our partners will help hospitals improve the diagnosis and treatment of cancer, cardiovascular disease and other critical illnesses. Our goal is to support the current needs of the nuclear medicine and molecular imaging community and assist in the growth and development of new diagnostics and therapeutics.”
 
The main focus of the first 70 MeV Cyclotron will be to commercially manufacture Sr-82 to ensure ample, stable, U.S.-based supply of Sr-82/Rb-82 generators for use in the diagnosis of cardiovascular disease. This important radiotracer has no current commercial supplier and only has U.S. and foreign-based supply from national labs.
 
Although the primary focus is the manufacture of Sr-82, the Cyclone 70 is capable of producing a wide variety of other radionuclides for both research and clinical applications. 
 
For more information: www.zevacor.com, www.iba-worldwide.com

Related Content

GE Healthcare Recalls Millennium Nuclear Medicine Systems
News | Nuclear Imaging | November 15, 2018
GE Healthcare announced it is recalling its Millennium Nuclear Medicine Systems due to an incident in which the the top...
Artificial Intelligence Predicts Alzheimer's Years Before Diagnosis
News | Neuro Imaging | November 14, 2018
Artificial intelligence (AI) technology improves the ability of brain imaging to predict Alzheimer’s disease, according...
Researchers Awarded 2018 Canon Medical Systems USA/RSNA Research Grants
News | Radiology Imaging | November 13, 2018
The Radiological Society of North America (RSNA) Research & Education (R&E) Foundation recently announced the...
Subtle Medical Showcases Artificial Intelligence for PET, MRI Scans at RSNA 2018
News | Artificial Intelligence | November 13, 2018
At the 2018 Radiological Society of North America annual meeting (RSNA 2018), Nov. 25-30 in Chicago, Subtle Medical...
University of Missouri Research Reactor First U.S. I-131 Supplier in 30 Years

MURR is the only supplier of I 131 in the United States and the first U.S. supplier since the 1980s. Image courtesy of University of Missouri

News | Radiopharmaceuticals and Tracers | November 13, 2018
The University of Missouri Research Reactor (MURR) recently shipped its first batch of Iodine-131 (I-131), a...
MEDraysintell Projects Increasing Mergers and Acquisitions in Nuclear Medicine
News | Nuclear Imaging | November 07, 2018
With the recent announcement by Novartis to acquire Endocyte , interest from the conventional pharmaceutical industry...
Feature | PET Imaging | November 07, 2018 | By Greg Freiherr
Positron emission tomography (PET) is getting ready to venture outside oncology, cardiology and mainstream neurology....
Podcast | PET Imaging | November 07, 2018
PET is getting ready to venture outside oncology, cardiology and mainstream neurology.
A PET/CT head and neck cancer scan.

A PET/CT head and neck cancer scan.

Feature | Nuclear Imaging | November 05, 2018 | By Sabyasachi Ghosh
“Experimental validation implemented in real-life situations and not theoretical claims exaggerating small advantages
PET Imaging Offers New Possibilities in Chronic Liver Disease Management

Hepatic 18F-FDG, 18F-FAC, and 18F-DFA accumulation are affected in a mouse model of autoimmune hepatitis. (A) Histochemical and immunohistochemical analyses of liver sections from vehicle- and ConA-treated mice. Scale bars represent 50 microns. Transverse PET/CT images (B) and quantification (C) of vehicle- and ConA-treated mice injected with 18F-FDG, 18F-FAC, and 18FDFA. Livers are outlined in a white dotted line. Quantification represents radiotracer accumulation in the liver normalized to a background organ. Image courtesy of Salas J.R., Chen B.Y., Wong A., et al.

News | PET Imaging | October 24, 2018
While liver biopsies are powerful and reliable, they are also invasive, painful, limited and subject to complications....